News › Industry News, News

Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio

August 31, 2020

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, has announced that the company’s field force is established and will begin introducing its prestige aesthetics portfolio, including the RHA Collection of dermal fillers, resilient hyaluronic acid and the HintMD financial technology platform, in the United States in September.
Read more at Business Wire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds
    • Medical Marketing Whiz Recognized With Healthcare Digital Marketing Excellence Award
    • Allergan Presents Early Data on Skin Quality Treatments for Patients Taking Weight-Loss Medications
    • ValueCap Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s
Advertisement